Population
Patients with obesity and metabolic syndrome
Design
Review
Authors
Loading...
Supports targeted pharmacotherapy for metabolic syndrome components except obesity; leaves open optimal long-term obesity strategies.
This review highlights the multifaceted pathogenesis of cardiovascular disease in obesity and metabolic syndrome, emphasizing the role of insulin resistance, adipokines, and the need for comprehensive lifestyle and pharmacological management.
Nikolopoulou et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: